Utime Signs NDA To Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc, Aims To Support Completion Of FDA Registration For Related Vaccines
Portfolio Pulse from Benzinga Newsdesk
Utime has signed a non-disclosure agreement to acquire Bowen Therapeutics Inc, a company involved in making monkeypox vaccines. The acquisition aims to support the completion of FDA registration for these vaccines.
August 28, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Utime's acquisition of Bowen Therapeutics could enhance its portfolio by adding monkeypox vaccines, potentially boosting its market position and aiding FDA registration.
The acquisition of Bowen Therapeutics by Utime is significant as it involves the addition of monkeypox vaccines to Utime's portfolio. This move could enhance Utime's market position and support the completion of FDA registration, potentially leading to increased investor interest and a positive impact on Utime's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90